检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:房思炼[1] 王大章[2] 杨西川[2] 李虹[3] 郑光勇[2] 张静仪[2]
机构地区:[1]中山大学附属第二医院口腔颌面外科 [2]四川大学华西口腔医学院 [3]四川大学华西基础医学院微生物教研室
出 处:《华西口腔医学杂志》2002年第2期89-91,共3页West China Journal of Stomatology
基 金:国家自然科学基金资助项目 (编号 3 9970 798)
摘 要:目的 :研究抗人血管内皮生长因子 (VEGF)单抗E1 1 抑制移植性人颊鳞癌血管生成 ,从而抑制颊癌生长的作用效果。方法 :接种人颊鳞癌BCaCD885细胞株的BALB c裸小鼠分别通过腹腔或瘤周皮下注射抗人VEGF单抗或生理盐水。每隔 3d测量瘤体积 1次 ,接种后第 18天处死裸鼠并称取瘤重 ,计算抑瘤率。结果 :①不同给药途径的抗人VEGF单抗对颊癌的生长均有明显的抑制作用 ,与生理盐水组相比较有显著性差异 ,其抑瘤率分别为 6 0 1%、6 9 9%。②腹腔、瘤周皮下两种注射方式比较 ,瘤周皮下组的抑瘤效果更为显著。结论 :肿瘤中的VEGF是抗肿瘤血管生成的理想靶目标 ,而抗人VEGF单抗又是该抑癌新途径的理想选择 。Objective:The purpose of this study was to apply the anti_human VEGF monoclonal antibody E\-\{11\}, which was generated against a synthetic peptide from the NH\-2 of the human VEGF (residues 1_26), to against VEGF in buccal carcinoma, and to examine the inhibition effect of the antibody on the carcinoma growth. Methods:E\-\{11\} was hypodermic and celiac injected, with 200 μg each from the first to the 15th day, into BALB/c nu/nu mice, which were transplanted with human buccal carcinoma. The saline was injected as the negative control. Mice were killed on the 18th day. The tumor weight was determined and the inhibition rate was calculated. Results:The growth of BCaCD885 carcinoma was dramatically inhibited in the E\-\{11\} group. There was a significant difference in tumor weight between the saline group and the E\-\{11\} groups during the observation period. The tumor growth inhibition rate in the mice hypodermically injected with E\-\{11\} reached 69.9%. Conclusion:The anti_human VEGF monoclonal antibody E\-\{11\} significantly inhibits tumor growth by blocking the action of VEGF, and without obvious side effects, therefore the anti_human VEGF monoclonal antibody could be applied clinically in the anti_angiogenic treatment of solid tumors.\;
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222